Summary: Aging weakens the blood-forming system by impairing hematopoietic stem cells (HSCs), which reduces immune competence and biases blood production toward inflammatory myeloid cells. A recent study identifies the protein MLKL as a surprising driver of this decline: beyond its established role in necroptosis, MLKL can act non-lethally to damage mitochondria in HSCs and accelerate their functional aging.
Traditionally known for executing necroptotic cell death, MLKL here performs a different role. Instead of destroying the cell, activated MLKL transiently accumulates on mitochondrial membranes in HSCs, disrupting mitochondrial structure and energy production. This organelle-directed activity reduces stem cell self-renewal and shifts differentiation away from lymphoid lineages, producing features characteristic of aged blood systems.
Key Findings
- HSC aging hallmarks: Stress-induced MLKL activation causes loss of self-renewal and a myeloid-biased output at the expense of lymphoid cells, undermining immune resilience.
- MLKL deletion rescues function: Genetic inactivation of MLKL preserves HSC regenerative capacity, reduces DNA damage, and maintains healthier immune cell production under stress and in aged animals.
- Organelle-level mechanism: Rather than altering gene transcription broadly, MLKL promotes aging through post-transcriptional, organelle-level changes—directly impairing mitochondrial membrane potential, morphology, and metabolic flux.
- Convergent stress hub: Diverse stressors (inflammation, replication stress, oncogenic signals) activate the RIPK3–MLKL axis, positioning MLKL as a central bottleneck linking multiple aging-related insults to mitochondrial dysfunction in HSCs.
Source: University of Tokyo
Hematopoietic stem cells normally balance self-renewal with production of all blood lineages. With age and repeated stress, HSCs produce fewer new cells, favor myeloid over lymphoid fates, and show accumulated damage that compromises immune responses. Known contributors include DNA damage, chronic low-grade inflammation, and changes to the bone marrow environment, but how these factors converge on HSC decline has been unclear.
Researchers at The University of Tokyo and St. Jude Children’s Research Hospital investigated whether the RIPK3–MLKL signaling axis, canonically linked to necroptosis, also mediates functional deterioration of HSCs without causing cell death. The study was led by Dr. Masayuki Yamashita, with contributions from Dr. Atsushi Iwama, Dr. Yuta Yamada, and colleagues. Their findings appear in Nature Communications (Volume 17, April 6, 2026).
Using genetic mouse models (wild-type, MLKL-deficient, and RIPK3-deficient), biosensor reporter mice that detect MLKL activation, and stress paradigms that mimic aging—such as inflammation, replication stress, and oncogenic challenge—the team assessed HSC function primarily via bone marrow transplantation assays. Complementary analyses included flow cytometry, ex vivo expansion, RNA sequencing, chromatin accessibility assays, high-resolution microscopy, metabolic profiling, and detailed mitochondrial studies.
The data reveal that MLKL activation in HSCs is typically transient and localized to mitochondria rather than triggering membrane rupture and necroptotic death. Mitochondrial MLKL reduced membrane potential, altered cristae and organelle morphology, and impaired metabolic output. These organelle defects produced classic aging phenotypes in HSCs: diminished self-renewal, impaired lymphoid differentiation, and myeloid skewing.
Crucially, genetic deletion or inactivation of MLKL preserved HSC function under stress and during chronological aging. MLKL-deficient HSCs maintained regenerative potential, produced a healthier spectrum of immune cells, showed reduced DNA damage, and retained mitochondrial integrity. These benefits occurred without major changes in global gene expression or chromatin accessibility, indicating a primary role for MLKL in post-transcriptional, organelle-level regulation of HSC aging.
These results have broad implications for aging biology and clinical care. By identifying MLKL as a point where diverse stress signals converge to damage mitochondria and drive HSC aging, the study points to mitochondrial protection and targeted modulation of necroptosis-related pathways as promising strategies to preserve blood system health. Such interventions could ultimately help patients recover more effectively from chemotherapy, radiation, or transplantation and mitigate age-related immune decline.
Dr. Yamashita notes that the discovery of this non-lethal, stress-responsive role for MLKL opens new avenues for therapeutic development focused on preserving mitochondrial function in stem cells and modulating MLKL activity without necessarily inducing cell death.
Key Questions Answered
A: In HSCs MLKL activation is brief and localized to mitochondria. That transient activation is sufficient to damage mitochondrial function but stops short of triggering the membrane disruption that causes necroptotic cell death.
A: The findings identify MLKL as a specific molecular target. Drugs that modulate MLKL activity or protect mitochondria could potentially preserve HSC function and help maintain a more youthful blood system during aging or after cytotoxic therapies.
A: This study focused on HSCs, but many stem cell types age through mitochondrial decline. The authors suggest that non-lethal roles of cell-death proteins like MLKL might operate more broadly in tissue aging, which merits further investigation.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The underlying journal paper was reviewed in full by our editorial team.
- Additional explanatory context was added by staff to aid clarity.
About this genetics and aging research news
Author: Project Coordination Office
Source: University of Tokyo
Contact: Project Coordination Office – University of Tokyo
Image: The image is credited to Neuroscience News
Original Research: Open access.
Title: Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging
Authors: Yuta Yamada, Jinjing Yang, Akiho Saiki-Tsuchiya, Yuji Watanabe, Shuhei Koide, Shin Murai, Yuriko Sorimachi, Yu Fukuda, Kenta Sumiyama, Hiroshi Sagara, Hiroyasu Nakano, Keiyo Takubo, Atsushi Iwama & Masayuki Yamashita. Nature Communications
DOI: 10.1038/s41467-026-71060-4
Abstract
Non-necroptotic MLKL function damages mitochondria and promotes hematopoietic stem cell aging
Hematopoietic stem cells endure many stressors but lose regenerative and lymphoid-producing capacities with age, often accumulating dysfunctional HSCs with impaired mitochondria. The molecular link between stress responses and functional decline has been unclear. This study shows multiple stress signals converge on the RIPK3–MLKL axis, leading to MLKL activation in HSC mitochondria. Activated MLKL impairs self-renewal and lymphoid differentiation without causing cell death, primarily mediating mitochondrial damage and reduced glycolytic flux during aging. These results establish the RIPK3–MLKL pathway as a key mediator of HSC aging and identify a necroptosis-independent role for MLKL in mitochondrial dysfunction.